6533b839fe1ef96bd12a654c
RESEARCH PRODUCT
Cytolytic T-cell clones against an autologous human melanoma: specificity study and definition of three antigens by immunoselection.
E KlehmannK H Meyer Zum BüschenfeldeThierry BoonAlexander KnuthT. Wölfelsubject
AdultCytotoxicity ImmunologicMalemedicine.drug_classT cellLymphocytechemical and pharmacologic phenomenaHuman leukocyte antigenBiologyMonoclonal antibodyLymphocyte ActivationAntigenAntigens NeoplasmmedicineHumansMelanomaMultidisciplinaryMelanomahemic and immune systemsT lymphocytemedicine.diseaseClone CellsCTL*medicine.anatomical_structureImmunologyT-Lymphocytes CytotoxicResearch Articledescription
Cytolytic T-lymphocyte (CTL) clones against an autologous melanoma (SK-MEL-29) were generated by mixed lymphocyte tumor culture and subsequent cloning of responder lymphocytes at limiting dilutions. These CTL clones lysed autologous melanoma but not autologous Epstein-Barr virus-transformed B cells and none of the allogeneic tumor targets included in the specificity analysis. The lysis of autologous melanoma targets could be inhibited by monoclonal antibodies against monomorphic HLA class I determinants. For proliferation of CTLs, the stimulation with the relevant target antigen on autologous tumor cells was essential. Immunoselection experiments carried out with two CTL clones revealed the existence of melanoma subclones that were resistant to lysis by the CTL clones used for immunoselection but were still lysed by other autologous CTL clones. This analysis allowed us to identify three stable simultaneously expressed antigens on the melanoma cells defined by autologous CTLs.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 1989-04-01 | Proceedings of the National Academy of Sciences of the United States of America |